Last reviewed · How we verify

Pharmacokinetics of certolizumab pegol

UCB Biopharma SRL · Phase 1 active Small molecule

Pharmacokinetics of certolizumab pegol is a Small molecule drug developed by UCB Biopharma SRL. It is currently in Phase 1 development. Also known as: PK.

At a glance

Generic namePharmacokinetics of certolizumab pegol
Also known asPK
SponsorUCB Biopharma SRL
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pharmacokinetics of certolizumab pegol

What is Pharmacokinetics of certolizumab pegol?

Pharmacokinetics of certolizumab pegol is a Small molecule drug developed by UCB Biopharma SRL.

Who makes Pharmacokinetics of certolizumab pegol?

Pharmacokinetics of certolizumab pegol is developed by UCB Biopharma SRL (see full UCB Biopharma SRL pipeline at /company/ucb-biopharma-srl).

Is Pharmacokinetics of certolizumab pegol also known as anything else?

Pharmacokinetics of certolizumab pegol is also known as PK.

What development phase is Pharmacokinetics of certolizumab pegol in?

Pharmacokinetics of certolizumab pegol is in Phase 1.

Related